PerkinElmer is pleased to announce the acquisition of ViaCell, Inc., regarded as the high-quality provider of umbilical cord stem cell preservation and research in the industry. 

PerkinElmer will now offer ViaCord®, enabling expectant families to preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. This complements our position as the world’s leading provider of newborn screening systems, and our growing offerings in prenatal and maternal health, including Ultrascreen®, our rapidly growing first-trimester prenatal risk assessment service offered through NTD Labs. 

ViaCord’s customers will continue to receive the high quality service they have come to expect, with the added benefit of PerkinElmer’s global resources, commitment to innovation and financial strength.   Cord blood units will continue to remain safely cryopreserved at ViaCord’s state-of-the-art processing laboratory and customer contracts will remain in place.

Both PerkinElmer and ViaCell share the same goal – to help save lives.  As the world’s leading provider of neonatal screening systems, PerkinElmer has helped identify more than 100,000 newborns at risk of inherited metabolic disorders.  ViaCord now offers expecting families the unique combination of cord blood expertise and the piece of mind that comes with PerkinElmer’s strength and stability.

For more information about the acquisition, go to:

Press Release

For more information about ViaCord, go to:

http://www.viacellinc.com/

http://www.viacord.com/